Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now official registry

Human Immunodeficiency Virus (HIV) clinical trials

Every US clinical trial registered for Human Immunodeficiency Virus (HIV) — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.

19 US clinical trials · 7 currently recruiting

The research picture

Human Immunodeficiency Virus (HIV) has 19 registered US clinical trials, 7 of them open to new participants right now — about 37% of the total.

7
recruiting participants now
37%
of trials open to enrollment
2
in Phase 3–4 (later-stage)
2
top sponsor: AbbVie

Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.

Active & Recent Trials

RECRUITING Phase 3 4,390 participants

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Merck Sharp & Dohme

NCT07044297

RECRUITING NA 2,000 participants

Persuasive Health Communication Intervention for HIV/HCV

Icahn School of Medicine at Mount Sinai

NCT05968573

RECRUITING Phase 4 500 participants

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

New York University

NCT06598397

RECRUITING NA 314 participants

Quitting Matters Human Immunodeficiency Virus Hybrid Trial

Wake Forest University Health Sciences

NCT06883097

RECRUITING NA 200 participants

e-HERO: Ending the HIV Epidemic in Rural Oklahoma

Northern Arizona University

NCT05664802

RECRUITING NA 189 participants

Project neuroARTEMIS

Wake Forest University Health Sciences

NCT06814275

RECRUITING NA 124 participants

The Trans-Led Care Study

Illinois Institute of Technology

NCT06880705

ACTIVE NOT RECRUITING NA 752 participants

Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk

April M Young

NCT05657106

COMPLETED 143 participants

New Strategies to Assess Anal Cancer Risk In Women

Emory University

NCT02873741

COMPLETED Phase 2 136 participants

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

PATH

NCT02165202

COMPLETED 100 participants

Evaluating Rewards-Based Adherence and Electronic Medication Monitoring in HIV-Positive Adolescents

St. Jude Children's Research Hospital

NCT01849393

COMPLETED Phase 1 65 participants

Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults

U.S. Army Medical Research and Development Command

NCT05423418

COMPLETED NA 61 participants

Tesamorelin Effects on Liver Fat and Histology in HIV

Massachusetts General Hospital

NCT02196831

COMPLETED Phase 1 54 participants

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

AbbVie

NCT04554966

COMPLETED Phase 2 48 participants

Romidepsin Plus 3BNC117 Phase 2a Study

Rockefeller University

NCT02850016

COMPLETED Phase 1 41 participants

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

AbbVie

NCT04223804

COMPLETED Phase 1 15 participants

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Janssen Research & Development

NCT05197075

COMPLETED Phase 1 14 participants

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

Merck Sharp & Dohme

NCT06783192

COMPLETED NA 11 participants

Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission

Johns Hopkins University

NCT01053741

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2
Phase 3 1
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Human Immunodeficiency Virus (HIV) Trial Landscape

ClinicalTrials.gov lists 19 US studies indexed under Human Immunodeficiency Virus (HIV), and 7 of those are currently open to recruitment — roughly 37% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Human Immunodeficiency Virus (HIV) shows 2 late-stage studies (Phase 3 and Phase 4 combined) alongside 7 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Human Immunodeficiency Virus (HIV) is led by AbbVie with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 19 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Human Immunodeficiency Virus (HIV)?

PlainTrial tracks 19 US clinical trials for Human Immunodeficiency Virus (HIV), of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Human Immunodeficiency Virus (HIV)?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →